ES2660372T8 - Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington - Google Patents
Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de HuntingtonInfo
- Publication number
- ES2660372T8 ES2660372T8 ES15736262T ES15736262T ES2660372T8 ES 2660372 T8 ES2660372 T8 ES 2660372T8 ES 15736262 T ES15736262 T ES 15736262T ES 15736262 T ES15736262 T ES 15736262T ES 2660372 T8 ES2660372 T8 ES 2660372T8
- Authority
- ES
- Spain
- Prior art keywords
- huntington
- procedures
- disease
- prevention
- substances
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14176609 | 2014-07-10 | ||
| EP14176609 | 2014-07-10 | ||
| PCT/EP2015/065795 WO2016005547A1 (en) | 2014-07-10 | 2015-07-10 | Substances and methods for the use in prevention and/or treatment in huntington's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2660372T3 ES2660372T3 (es) | 2018-03-22 |
| ES2660372T8 true ES2660372T8 (es) | 2019-02-12 |
Family
ID=51162585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15736262.5T Active ES2660372T3 (es) | 2014-07-10 | 2015-07-10 | Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US10053518B2 (es) |
| EP (1) | EP3166660B1 (es) |
| JP (1) | JP2017523165A (es) |
| CN (1) | CN106687475A (es) |
| AU (1) | AU2015286606A1 (es) |
| DK (1) | DK3166660T3 (es) |
| ES (1) | ES2660372T3 (es) |
| PL (1) | PL3166660T3 (es) |
| WO (1) | WO2016005547A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2954738A1 (en) * | 2014-07-29 | 2016-02-04 | Neurimmune Holding Ag | Human-derived anti-huntingtin (htt) antibodies and uses thereof |
| CN112390884B (zh) * | 2019-04-09 | 2022-07-08 | 苏州大学 | Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用 |
| CN116535510B (zh) * | 2023-06-30 | 2023-11-10 | 四川省医学科学院·四川省人民医院 | 一种抗人pla2r的抗体、试剂盒及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7375194B2 (en) * | 2002-01-28 | 2008-05-20 | California Institute Of Technology | Antibodies that bind to an epitope on the Huntington's disease protein |
| AT413336B (de) * | 2003-09-12 | 2006-02-15 | Mattner Frank Dr | Apherese-vorrichtung |
| US20050112139A1 (en) * | 2003-10-23 | 2005-05-26 | Nmk Research, Llc | Immunogenic composition and method of developing a vaccine based on factor H binding sites |
| EP2086573B1 (en) * | 2006-10-09 | 2020-11-25 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
| ES2652643T3 (es) * | 2011-04-12 | 2018-02-05 | Centre National De La Recherche Scientifique (C.N.R.S.) | Péptidos terapéuticos y su uso contra la corea de Huntington |
-
2015
- 2015-07-10 AU AU2015286606A patent/AU2015286606A1/en not_active Abandoned
- 2015-07-10 US US15/323,461 patent/US10053518B2/en not_active Expired - Fee Related
- 2015-07-10 CN CN201580048528.9A patent/CN106687475A/zh active Pending
- 2015-07-10 EP EP15736262.5A patent/EP3166660B1/en not_active Not-in-force
- 2015-07-10 PL PL15736262T patent/PL3166660T3/pl unknown
- 2015-07-10 DK DK15736262.5T patent/DK3166660T3/en active
- 2015-07-10 JP JP2017501203A patent/JP2017523165A/ja not_active Ceased
- 2015-07-10 ES ES15736262.5T patent/ES2660372T3/es active Active
- 2015-07-10 WO PCT/EP2015/065795 patent/WO2016005547A1/en not_active Ceased
-
2018
- 2018-07-02 US US16/025,095 patent/US20180327513A1/en not_active Abandoned
-
2020
- 2020-08-18 US US16/996,031 patent/US20210040236A1/en not_active Abandoned
-
2021
- 2021-11-05 US US17/520,141 patent/US12065509B2/en active Active
-
2024
- 2024-07-10 US US18/768,852 patent/US20250051480A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US12065509B2 (en) | 2024-08-20 |
| PL3166660T3 (pl) | 2018-07-31 |
| US10053518B2 (en) | 2018-08-21 |
| US20220073650A1 (en) | 2022-03-10 |
| JP2017523165A (ja) | 2017-08-17 |
| US20210040236A1 (en) | 2021-02-11 |
| US20180327513A1 (en) | 2018-11-15 |
| ES2660372T3 (es) | 2018-03-22 |
| US20170145117A1 (en) | 2017-05-25 |
| AU2015286606A1 (en) | 2017-01-12 |
| US20250051480A1 (en) | 2025-02-13 |
| EP3166660A1 (en) | 2017-05-17 |
| WO2016005547A1 (en) | 2016-01-14 |
| CN106687475A (zh) | 2017-05-17 |
| EP3166660B1 (en) | 2017-12-13 |
| DK3166660T3 (en) | 2018-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281793A (en) | Use of cannabinoids in the treatment of epilepsy | |
| IL283086A (en) | Use of cannabidiol in the treatment of tuberous sclerosis complex | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| HUE055334T2 (hu) | Szerves vegyületek és azok alkalmazása központi idegrendszeri betegségek kezelésében vagy megelõzésében | |
| IL251530A0 (en) | Use of cannabinoids in the treatment of skeletal muscle atrophy | |
| PL3157511T3 (pl) | Zastosowanie kannabinoidów w leczeniu padaczki | |
| PT3185957T (pt) | Patisiran para utilização no tratamento de amoloidose mediada por transtirretina | |
| GB201515986D0 (en) | Use of cannabinoids in the treatment of mental disorders | |
| PL4374873T3 (pl) | Środek do stosowania w leczeniu lub zapobieganiu schorzeniom okulistycznym | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| IL254142B (en) | Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent | |
| HRP20180260T1 (hr) | Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja | |
| CY1126258T1 (el) | Ενωσεις ινδολινονης και χρηση αυτων στη θεραπεια ινωτικων ασθενειων | |
| HRP20181490T1 (hr) | Spojevi 1, 3, 4-tiadiazola i njihova upotreba u liječenju raka | |
| SMT202500469T1 (it) | Combinazione farmaceutica comprendente ponesimod e suo utilizzo nel trattamento della sclerosi multipla | |
| DK3153511T3 (da) | 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme | |
| HUE045025T2 (hu) | Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére | |
| PL3732294T3 (pl) | Tymohydrochinon do stosowania w leczeniu hiperglikemii | |
| GB2564459B (en) | Use of cannabinoids in the treatment of a neurodegenerative disease or disorder | |
| IL247435A0 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| CY1127309T1 (el) | Ebselen για χρηση στη θεραπεια της νοσου meniep | |
| ES3064252T3 (en) | Meat treatment composition and use thereof | |
| CL2015000537A1 (es) | Siarn y su uso en los métodos y composiciones para el tratamiento y/o prevención de enfermedades de los ojos. | |
| HRP20180071T1 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
| GB201504387D0 (en) | Materials and methods for the treatment of vascular disease |